

2022 BENCHMARKING DATA



(2022) My organization's use of remote/risk-based monitoring will increase over the next two years (n=260)




(2021) My organization's use of remote/risk-based monitoring will increase over the next two years (n=272)




(2022) Clinical trial designs at my company are focusing on enrolling a demographically diverse population (n=260)




(2021) Clinical trial designs at my company are focusing on enrolling a demographically diverse population (n=272)



(2020) Clinical trial designs at my company are focusing on enrolling a demographically diverse population (n=329)







(2022) My organization's interest in mobile health (mHealth) applications for clinical trials will increase over the next two years (n=260)




(2021) My organization's interest in mobile health (mHealth) applications for clinical trials will increase over the next two years (n=272)




(2020) My organization's interest in mobile health (mHealth) applications for clinical trials will increase over the next two years (n=329)




(2022) My organization will spread its outsourced work over more CROs over the next two years (n=260)




(2021) My organization will spread its outsourced work over more CROs over the next two years (n=272)




(2020) My organization will spread its outsourced work over more CROs over the next two years (n=329)




(2019) My organization will spread its outsourced work over more CROs over the next two years (n=508)







(2022) Rare disease/ orphan drugs will comprise much more of my company's development activities over the next two years (n=260)




(2021) Rare disease/ orphan drugs will comprise much more of my company's development activities over the next two years (n=272)




(2020) Rare disease/ orphan drugs will comprise much more of my company's development activities over the next two years (n=329)




(2019) My organization will spread its outsourced work over more CROs over the next two years (n=508)




(2022) Virtual/ decentralized clinical trials will be a major component of my organization's clinical portfolio within two years (n=260)




(2021) Virtual/ decentralized clinical trials will be a major component of my organization's clinical portfolio within two years (n=272)



(2020) Virtual/ decentralized clinical trials will be a major component of my organization's clinical portfolio within two years (n=329)






(2022) Management of CROs and other service providers is taking up too much of my time (n=260)




(2021) Management of CROs and other service providers is taking up too much of my time (n=272)




(2022) My organization will increase the use of specialized site identification companies over the next two years (n=260)



(2021) My organization will increase the use of specialized site identification companies over the next two years (n=272)



(2020) My organization will increase the use of specialized site identification companies over the next two years (n=329)



(2022) My organization will run a clinical trial within the next two years where the majority of activities occur in the participant's home (n=260)



(2021) My organization will run a clinical trial within the next two years where the majority of activities occur in the participant's home (n=272)



(2020) My organization will run a clinical trial within the next two years where the majority of activities occur in the participant's home (n=329)

